UPDATE 1-FDA clears Merck's Keytruda for cancers with certain genetic traits

May 23 (Reuters) - Merck & Co's immunotherapy Keytruda chalked up another approval on Tuesday as the U.S. Food and Drug Administration said the cancer medicine can be used to treat children and adults who carry a specific genetic feature regardless of where the disease originated.